Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on September 25, 2003; DOI 10.1182/blood-2003-06-2043.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-06-2043v1
103/2/689    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Novak, A. J
Right arrow Articles by Jelinek, D. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Novak, A. J
Right arrow Articles by Jelinek, D. F
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted June 27, 2003
Accepted September 15, 2003

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

Anne J Novak, Jaime R Darce, Bonnie K Arendt, Brandon Harder, Kathy Henderson, Wayne Kindsvogel, Jane A Gross, Philip R Greipp, and Diane F Jelinek*

Department of Immunology, Mayo Foundation, Rochester, MN, USA
Department of Internal Medicine, Mayo Foundation, Rochester, MN, USA
Zymogenetics, Seattle, WA, USA

* Corresponding author; email: jelinek.diane{at}mayo.edu.

Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of anti-apoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that BLyS, a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of three known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of MM patients. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications as they may be potential therapeutic targets.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
K. S. Kim, J.-Y. Park, I. Jou, and S. M. Park
Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia
J. Leukoc. Biol., August 1, 2009; 86(2): 349 - 359.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Gupta, S. R. Dillon, S. C. Ziesmer, A. L. Feldman, T. E. Witzig, S. M. Ansell, J. R. Cerhan, and A. J. Novak
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
Blood, May 21, 2009; 113(21): 5206 - 5216.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al.
Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma
Cancer Res., May 15, 2009; 69(10): 4217 - 4224.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Blood, May 7, 2009; 113(19): 4614 - 4626.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Salzer, C. Bacchelli, S. Buckridge, Q. Pan-Hammarstrom, S. Jennings, V. Lougaris, A. Bergbreiter, T. Hagena, J. Birmelin, A. Plebani, et al.
Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes
Blood, February 26, 2009; 113(9): 1967 - 1976.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. L. Good, D. T. Avery, and S. G. Tangye
Resting Human Memory B Cells Are Intrinsically Programmed for Enhanced Survival and Responsiveness to Diverse Stimuli Compared to Naive B Cells
J. Immunol., January 15, 2009; 182(2): 890 - 901.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. E. Khuda, W. M. Loo, S. Janz, B. Van Ness, and L. D. Erickson
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors
J. Immunol., December 1, 2008; 181(11): 7537 - 7549.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Carbonatto, P. Yu, M. Bertolino, E. Vigna, S. Steidler, L. Fava, C. Daghero, B. Roattino, M. Onidi, M. Ardizzone, et al.
Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept
Toxicol. Sci., September 1, 2008; 105(1): 200 - 210.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. Hardenberg, L. Fernandez, J. Hendriks, K. Chebli, C. Jacquet, M. Sitbon, M. Hahne, and J. P. Medema
APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis
J. Leukoc. Biol., August 1, 2008; 84(2): 380 - 388.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Bossen, T. G. Cachero, A. Tardivel, K. Ingold, L. Willen, M. Dobles, M. L. Scott, A. Maquelin, E. Belnoue, C.-A. Siegrist, et al.
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts
Blood, February 1, 2008; 111(3): 1004 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. R. Darce, B. K. Arendt, X. Wu, and D. F. Jelinek
Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation
J. Immunol., December 1, 2007; 179(11): 7276 - 7286.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. C. Ryan, M. Hering, D. Peckham, C. F. McDonagh, L. Brown, K. M. Kim, D. L. Meyer, R. F. Zabinski, I. S. Grewal, and P. J. Carter
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Mol. Cancer Ther., November 1, 2007; 6(11): 3009 - 3018.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Neri, S. Kumar, M. T. Fulciniti, S. Vallet, S. Chhetri, S. Mukherjee, Y. Tai, D. Chauhan, P. Tassone, S. Venuta, et al.
Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model
Clin. Cancer Res., October 1, 2007; 13(19): 5903 - 5909.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. G. Mueller, C. Boix, W.-H. Kwan, C. Daussy, E. Fournier, W. H. Fridman, and T. J. Molina
Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation
J. Leukoc. Biol., September 1, 2007; 82(3): 567 - 575.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. R. Darce, B. K. Arendt, S. K. Chang, and D. F. Jelinek
Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells
J. Immunol., May 1, 2007; 178(9): 5612 - 5622.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
Y. Oki, G. V. Georgakis, T.-S. Migone, L. W. Kwak, and A. Younes
Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma
Haematologica, February 1, 2007; 92(2): 269 - 270.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Kothlow, I. Morgenroth, Y. Graef, K. Schneider, I. Riehl, P. Staeheli, P. Schneider, and B. Kaspers
Unique and conserved functions of B cell-activating factor of the TNF family (BAFF) in the chicken
Int. Immunol., February 1, 2007; 19(2): 203 - 215.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Chiu, W. Xu, B. He, S. R. Dillon, J. A. Gross, E. Sievers, X. Qiao, P. Santini, E. Hyjek, J.-w. Lee, et al.
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
Blood, January 15, 2007; 109(2): 729 - 739.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
D. Sene, N. Limal, P. Ghillani-Dalbin, D. Saadoun, J.-C. Piette, and P. Cacoub
Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF)
Rheumatology, January 1, 2007; 46(1): 65 - 69.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Schwaller, P. Schneider, P. Mhawech-Fauceglia, T. McKee, S. Myit, T. Matthes, J. Tschopp, O. Donze, F.-A. Le Gal, and B. Huard
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness
Blood, January 1, 2007; 109(1): 331 - 338.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. K. Chang, B. K. Arendt, J. R. Darce, X. Wu, and D. F. Jelinek
A role for BLyS in the activation of innate immune cells
Blood, October 15, 2006; 108(8): 2687 - 2694.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A Becker-Merok, C Nikolaisen, and H C Nossent
B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time
Lupus, September 1, 2006; 15(9): 570 - 576.
[Abstract] [PDF]


Home page
JEMHome page
A. Kukreja, A. Hutchinson, K. Dhodapkar, A. Mazumder, D. Vesole, R. Angitapalli, S. Jagannath, and M. V. Dhodapkar
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
J. Exp. Med., August 7, 2006; 203(8): 1859 - 1865.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al.
Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.
Cancer Res., July 1, 2006; 66(13): 6675 - 6682.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Fu, Y.-C. Lin-Lee, L. V. Pham, A. Tamayo, L. Yoshimura, and R. J. Ford
Constitutive NF-{kappa}B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
Blood, June 1, 2006; 107(11): 4540 - 4548.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Bischof, S. F. Elsawa, G. Mantchev, J. Yoon, G. E. Michels, A. Nilson, S. L. Sutor, J. L. Platt, S. M. Ansell, G. von Bulow, et al.
Selective activation of TACI by syndecan-2
Blood, April 15, 2006; 107(8): 3235 - 3242.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. F. Elsawa, A. J. Novak, D. M. Grote, S. C. Ziesmer, T. E. Witzig, R. A. Kyle, S. R. Dillon, B. Harder, J. A. Gross, and S. M. Ansell
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
Blood, April 1, 2006; 107(7): 2882 - 2888.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
T. Matsumoto and M. Abe
Myeloma-Bone Interaction: A Vicious Cycle
IBMS BoneKEy, March 1, 2006; 3(3): 8 - 14.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. J. Novak, D. M. Grote, S. C. Ziesmer, M. P. Kline, M. K. Manske, S. Slager, T. E. Witzig, T. Shanafelt, T. G. Call, N. E. Kay, et al.
Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders
J. Clin. Oncol., February 20, 2006; 24(6): 983 - 987.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting
B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells
J. Immunol., September 1, 2005; 175(5): 2814 - 2824.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Shaughnessy Jr
APRIL showers cause CLL and myeloma to flower
Blood, August 1, 2005; 106(3): 766 - 767.
[Full Text] [PDF]


Home page
Int ImmunolHome page
X. Zhang, C.-S. Park, S.-O. Yoon, L. Li, Y.-M. Hsu, C. Ambrose, and Y. S. Choi
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors
Int. Immunol., June 1, 2005; 17(6): 779 - 788.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival
Blood, June 1, 2005; 105(11): 4429 - 4436.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Bellucci, E. P. Alyea, S. Chiaretti, C. J. Wu, E. Zorn, E. Weller, B. Wu, C. Canning, R. Schlossman, N. C. Munshi, et al.
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
Blood, May 15, 2005; 105(10): 3945 - 3950.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al.
Identification of proteoglycans as the APRIL-specific binding partners
J. Exp. Med., May 2, 2005; 201(9): 1375 - 1383.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. A. Ogden, J. D. Pound, B. K. Batth, S. Owens, I. Johannessen, K. Wood, and C. D. Gregory
Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt's Lymphoma
J. Immunol., March 1, 2005; 174(5): 3015 - 3023.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Huang, M. Di Liberto, A. F. Cunningham, L. Kang, S. Cheng, S. Ely, H.-c. Liou, I. C. M. MacLennan, and S. Chen-Kiang
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1
PNAS, December 21, 2004; 101(51): 17789 - 17794.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. Q. Zhang, C. Okumura, T. McCarty, M. S. Shin, P. Mukhopadhyay, M. Hori, T. A. Torrey, Z. Naghashfar, J. X. Zhou, C. H. Lee, et al.
Evidence for Selective Transformation of Autoreactive Immature Plasma Cells in Mice Deficient in Fasl
J. Exp. Med., December 6, 2004; 200(11): 1467 - 1478.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. J. Novak, D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, et al.
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
Blood, October 15, 2004; 104(8): 2247 - 2253.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Ramanujam, X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson
Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus
J. Immunol., September 1, 2004; 173(5): 3524 - 3534.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
W Stohl
A therapeutic role for BLyS antagonists
Lupus, May 1, 2004; 13(5): 317 - 322.
[Abstract] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020